News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-31 pm EDT			5-day change	1st Jan Change
8.685 ^USD	-20.47%		+156.95%	+232.76%

May. 31	Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	MT
May. 31	Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	08:02am	BU
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	07:01pm	BU
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	May. 31	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	May. 31	MT
Sector Update: Health Care	May. 31	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	May. 31	MT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 30	BU
Health Care Stocks Steady -- Health Care Roundup	May. 30	DJ
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival	May. 30	CI
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	May. 30	MT
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar	May. 30	MT
Summit Therapeutics Shares Triple After Drug Candidate Data	May. 30	DJ
Summit Therapeutics cancer therapy succeeds in late-stage China study	May. 30	RE
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China	May. 30	BU
Summit Therapeutics Stock Trading Halted, Pending Material News Release	May. 30	MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon	May. 24	MT
Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced	May. 24	MT
Top Premarket Decliners	May. 24	MT
Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	May. 07	MT
Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Summary

Filters